The HTRA2 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 cell line. This product provides a loss-of-function model for the HTRA2 gene, created through CRISPR/Cas9-mediated gene disruption. The polyclonal format yields a heterogeneous knockout cell pool, rendering it suitable for studying population-level phenotypic effects without clonal selection bias. Researchers can utilize this model to investigate the functional consequences of HTRA2 ablation in a hepatic adenocarcinoma background, enabling dissection of its roles in apoptosis regulation and mitochondrial quality control.
SK-HEP-1 is a widely employed human hepatic adenocarcinoma cell line established from the ascitic fluid of a male patient. These epithelial cells serve as a well-characterized model for hepatocellular carcinoma (HCC) and are frequently utilized in cancer biology, drug metabolism, and signal transduction studies. Their robust growth characteristics and hepatic origin make them an ideal host for exploring tumor cell survival mechanisms. Combining the SK-HEP-1 background with HTRA2 knockout offers a unique platform to examine how the loss of a mitochondrial protease influences cancer cell fate and stress responses.
HTRA2 encodes a mitochondrial serine protease with dual functions in apoptosis and mitochondrial protein homeostasis. Upon mitochondrial outer membrane permeabilization (MOMP), HTRA2 is released into the cytosol where it cleaves and inactivates XIAP, thereby relieving caspase inhibition and promoting caspase-dependent and -independent cell death. Downstream targets include caspases such as CASP3 and CASP9, while upstream regulators encompass reactive oxygen species (ROS), PINK1, and Bcl-2 family proteins. Additionally, HTRA2 participates in the mitochondrial unfolded protein response by degrading misfolded proteins, an activity essential for organellar health. The protein interacts with PARL and PINK1, key components linked to Parkinson??s disease and mitophagy pathways.
In the SK-HEP-1 hepatocellular carcinoma context, disruption of HTRA2 allows researchers to interrogate its pro-apoptotic tumor suppressor potential and its contribution to mitochondrial quality control under cancer-relevant conditions. Loss of HTRA2 may confer resistance to intrinsic apoptosis inducers, providing a system to study drug resistance mechanisms and to screen for compounds that bypass apoptotic blocks. Moreover, the hepatic adenocarcinoma environment, coupled with mitochondrial stress, can mimic aspects of neurodegeneration, thereby opening avenues for Parkinson??s disease research, particularly the interplay between HTRA2, PINK1, and PARK2.
Typical applications of this polyclonal knockout model include apoptosis assays (e.g., Annexin V/PI flow cytometry, caspase activity measurements), mitochondrial membrane potential analysis using JC-1 staining, ROS detection, cell viability assays (MTT), and Western blotting for HTRA2, XIAP, and cleaved caspases. RT-qPCR can be employed to quantify apoptosis-related gene expression, while immunofluorescence enables visualization of mitochondrial protein translocation. This model is well-suited for mechanistic studies of intrinsic apoptosis, mitochondrial dysfunction, and for evaluating therapeutic agents in cancer and neurodegenerative disease contexts. For further details on experimental protocols and product specifications, please contact Ascent Research.
